Ulcerative Colitis
📧 Sign up to get email alerts when something new happens for Ulcerative Colitis.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS trial_result · 2019-07-08Clinical Trial Update: Investigation of the Faecal Loss of Vedolizumab and Its Role in Influencing Serum Drug Levels, Outcomes and Response in Ulcerative Colitis [Phase 4]
Phase 4 clinical trial investigating fecal loss of vedolizumab and its impact on serum drug levels, outcomes, and response in ulcerative col…
-
CLINICAL_TRIALS trial_result · 2019-07-05Clinical Trial Update: MEDI7183 Phase 2 Study in Japanese Ulcerative Colitis Patients [Phase 2]
Phase 2 study of MEDI7183 in Japanese patients with ulcerative colitis completed; results posted in 2019.
-
CLINICAL_TRIALS trial_result · 2019-06-28Clinical Trial Update: Hypnotherapy for Prevention of Relapse in Ulcerative Colitis: a Randomised, Single-blind, Controlled Clinical Trial [NA]
A randomized, single-blind trial evaluated hypnotherapy for preventing relapse in ulcerative colitis; the study was terminated with results …
-
CLINICAL_TRIALS trial_result · 2019-06-27Clinical Trial Update: Abrilumab (AMG 181) in Adults With Moderate to Severe Ulcerative Colitis [Phase 2]
Phase 2 trial results for Abrilumab (AMG 181) in adults with moderate to severe Ulcerative Colitis have been completed with results posted.
-
FDA approval · 2019-06-21FDA Approved: MESALAMINE RECTAL — Original Application (Amring Pharmaceuticals Inc.)
FDA approved Amring Pharmaceuticals' Mesalamine Rectal as an Original Application (ANDA 208362), authorizing a generic mesalamine rectal pro…
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS trial_result · 2019-06-20Clinical Trial Update: A Study to Evaluate the Safety, Tolerability and Microbiome Dynamics of SER-287 in Subjects With Mild-to-Moderate Ulcerative Colitis [Phase 1]
Phase 1 trial assessing safety, tolerability, and microbiome dynamics of SER-287 in mild-to-moderate ulcerative colitis completed with resul…
-
CLINICAL_TRIALS trial_result · 2019-06-19Clinical Trial Update: Safety, Efficacy, and Tolerability Study of PF-06480605 in Subjects With Moderate to Severe Ulcerative Colitis. [Phase 2]
Phase 2 trial evaluating safety, efficacy, and tolerability of PF-06480605 in moderate to severe ulcerative colitis has completed with resul…
-
FDA approval · 2019-06-13FDA Approved: AMJEVITA — Supplemental Application (Nuvaila Limited)
The FDA approved a supplemental application for AMJEVITA (adalimumab-atto) submitted by Nuvaila Limited.
-
EMA safety_alert · 2019-05-17Restrictions in use of Xeljanz while EMA reviews risk of blood clots in lungs
The EMA announced restrictions on the use of Xeljanz (tofacitinib) while it reviews the risk of blood clots in the lungs, indicating potenti…
-
CLINICAL_TRIALS trial_result · 2019-05-13Clinical Trial Update: Special Investigation in Patients With Ulcerative Colitis
A completed clinical trial update investigating ulcerative colitis, with results posted in 2019.
-
FDA approval · 2019-05-09FDA Approved: MESALAMINE — Original Application (Teva Pharmaceuticals USA, Inc.)
The FDA approved Teva Pharmaceuticals USA, Inc.'s original application for mesalamine (mesalamine), granting a generic drug approval.
-
FDA approval · 2019-05-07FDA Approved: ENTYVIO — Supplemental Application (Takeda Pharmaceuticals America, Inc.)
FDA approves a supplemental application for ENTYVIO (vedolizumab) submitted by Takeda Pharmaceuticals America, Inc.
-
CLINICAL_TRIALS trial_result · 2019-05-07Clinical Trial Update: Budesonide vs. Mesalazine vs. Budesonide/Mesalazine Suppository Combination Therapy in Acute Ulcerative Proctitis [Phase 2]
Phase 2 trial comparing budesonide, mesalazine, and budesonide/mesalazine suppository therapy in acute ulcerative proctitis has completed.
-
FDA approval · 2019-05-06FDA Approved: ENTYVIO — Supplemental Application (Takeda Pharmaceuticals America, Inc.)
The FDA approved a supplemental application for ENTYVIO (vedolizumab) submitted by Takeda Pharmaceuticals America, Inc.
-
FDA approval · 2019-04-23FDA Approved: AZATHIOPRINE — Supplemental Application (Zydus Lifesciences Limited)
FDA approved a supplemental application for azathioprine from Zydus Lifesciences Limited.
-
FDA approval · 2019-04-23FDA Approved: AZATHIOPRINE — Supplemental Application (Rising Pharma Holdings, Inc.)
The FDA approved a supplemental application for azathioprine from Rising Pharma Holdings, Inc., confirming a new generic form of the drug.
-
FDA approval · 2019-04-19FDA Approved: MESALAMINE — Original Application (Rising Pharma Holdings, Inc.)
The FDA approved Rising Pharma Holdings' original ANDA for Mesalamine, a generic formulation of the anti-inflammatory drug used to treat ulc…
-
CLINICAL_TRIALS trial_result · 2019-04-18Clinical Trial Update: Long-Term Safety Of PF-00547659 In Ulcerative Colitis [Phase 2]
Phase 2 trial update reporting long-term safety data for PF-00547659 in ulcerative colitis.
-
CLINICAL_TRIALS trial_result · 2019-04-17Clinical Trial Update: Telemedicine in Patients With Inflammatory Bowel Disease (TELE-IBD) [Phase 3]
Phase 3 trial update on telemedicine for inflammatory bowel disease, including Crohn's disease and related conditions, completed with result…
-
CLINICAL_TRIALS trial_result · 2019-04-10Clinical Trial Update: Safety and Efficacy of Andecaliximab (GS-5745) in Adults With Moderately to Severely Active Ulcerative Colitis [Phase 2, Phase 3]
Clinical trial update for Andecaliximab (GS-5745) in adults with moderately to severely active ulcerative colitis; trial phases 2 and 3 were…
-
CLINICAL_TRIALS trial_result · 2019-04-02Clinical Trial Update: An Efficacy and Safety Study of LYC-30937-EC in Subjects With Active Ulcerative Colitis [Phase 2]
Phase 2 trial update on LYC-30937-EC in active ulcerative colitis; results posted after completion.
-
CLINICAL_TRIALS trial_result · 2019-03-27Clinical Trial Update: Open-label Extension Study to Assess Safety and Tolerability of LYC-30937-EC in Subjects With Active Ulcerative Colitis [Phase 2]
Open-label extension study to assess safety and tolerability of LYC-30937-EC in active ulcerative colitis (Phase 2) has been terminated; res…
-
CLINICAL_TRIALS trial_result · 2019-03-20Clinical Trial Update: Phase III Study of MLN0002 (300 mg) in the Treatment of Ulcerative Colitis [Phase 3]
Phase III study of MLN0002 (300 mg) in ulcerative colitis has completed with results posted.
-
FDA approval · 2019-03-12FDA Approved: MESALAMINE — Supplemental Application (Teva Pharmaceuticals USA, Inc.)
The FDA approved a supplemental application for Mesalamine from Teva Pharmaceuticals USA, Inc., updating the product labeling.
-
CLINICAL_TRIALS trial_result · 2019-03-12Clinical Trial Update: An Open-label Study of Vedolizumab (MLN0002) in Participants With Ulcerative Colitis and Crohn's Disease [Phase 3]
Open-label Phase 3 trial update of vedolizumab in ulcerative colitis and Crohn's disease; study completed with results posted.